These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 26058994

  • 1. Drug-Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein.
    Ando A, Sasago S, Ohzone Y, Miyamoto Y.
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):549-58. PubMed ID: 26058994
    [Abstract] [Full Text] [Related]

  • 2. Identification of human cytochrome P450 enzymes involved in the metabolism of a novel к-opioid receptor agonist, nalfurafine hydrochloride.
    Ando A, Oshida K, Fukuyama S, Watanabe A, Hashimoto H, Miyamoto Y.
    Biopharm Drug Dispos; 2012 Jul; 33(5):257-64. PubMed ID: 22581509
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
    Nakao K, Hirakata M, Miyamoto Y, Kainoh M, Wakasa Y, Yanagita T.
    J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
    [Abstract] [Full Text] [Related]

  • 5. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
    Nagase H, Fujii H.
    Curr Pharm Des; 2013 Jan; 19(42):7400-14. PubMed ID: 23448474
    [Abstract] [Full Text] [Related]

  • 6. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
    Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, Kikuchi K, Kato T, Okano K, Gershwin ME, Miyakawa H.
    Eur J Pharmacol; 2005 Aug 22; 518(2-3):133-9. PubMed ID: 16055114
    [Abstract] [Full Text] [Related]

  • 7. The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
    Nemoto T, Yamamoto N, Wada N, Harada Y, Tomatsu M, Ishihara M, Hirayama S, Iwai T, Fujii H, Nagase H.
    Bioorg Med Chem Lett; 2013 Jan 01; 23(1):268-72. PubMed ID: 23200250
    [Abstract] [Full Text] [Related]

  • 8. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
    Miyamoto Y, Oh T, Aihara E, Ando A.
    Handb Exp Pharmacol; 2022 Jan 01; 271():455-472. PubMed ID: 33201326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
    Nakao K, Togashi Y, Honda T, Momen S, Umeuchi H, Sakakibara S, Tanaka T, Okano K, Mochizuki H.
    Eur J Pharmacol; 2012 Nov 15; 695(1-3):57-61. PubMed ID: 22981641
    [Abstract] [Full Text] [Related]

  • 11. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
    Dunn A, Windisch K, Ben-Ezra A, Pikus P, Morochnik M, Erazo J, Reed B, Kreek MJ.
    Psychopharmacology (Berl); 2020 Aug 15; 237(8):2405-2418. PubMed ID: 32435819
    [Abstract] [Full Text] [Related]

  • 12. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H, Hirabayashi H, Amano N, Moriwaki T.
    Drug Metab Dispos; 2013 Apr 15; 41(4):683-8. PubMed ID: 23340958
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
    Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, Kurihara M, Yanagita T, Suzuki H.
    Am J Nephrol; 2012 Apr 15; 36(2):175-83. PubMed ID: 22868684
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
    Schattauer SS, Kuhar JR, Song A, Chavkin C.
    Cell Signal; 2017 Apr 15; 32():59-65. PubMed ID: 28088389
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
    Nakao K, Hasebe K, Yoshikawa S, Ikeda K, Hirakata M, Miyamoto Y, Mochizuki H.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov 15; 30(5-6):185-91. PubMed ID: 21226314
    [Abstract] [Full Text] [Related]

  • 20. Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice.
    Zhang Y, Kreek MJ.
    Neuropharmacology; 2020 Oct 01; 176():108244. PubMed ID: 32702404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.